Trefoil Therapeutics

Executive Summary

Trefoil Therapeutics is a private biopharmaceutical company dedicated to developing small molecule therapies that restore vision by harnessing the regenerative properties of corneal endothelial and epithelial cells. Founded in 2012 and headquartered in San Diego, the company addresses corneal diseases affecting millions of patients, such as Fuchs endothelial corneal dystrophy and other conditions leading to corneal edema and vision loss. Trefoil's approach leverages the inherent regenerative capacity of endogenous corneal cells, aiming to provide non-surgical alternatives to corneal transplantation. The company's lead candidate is progressing through Phase 2 clinical development, focusing on safety and efficacy in promoting corneal endothelial cell regeneration. With a strong scientific foundation in cell biology and ophthalmology, Trefoil has the potential to disrupt the current standard of care, which relies heavily on donor tissue availability and invasive procedures. The company's pipeline remains focused on corneal indications, with potential expansion into other anterior segment diseases. As a privately held entity, Trefoil continues to attract interest from investors and strategic partners seeking innovative regenerative therapies in ophthalmology.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for lead candidate in Fuchs endothelial corneal dystrophy40% success
• H2 2026Series C financing or strategic partnership announcement60% success
• Q3 2026FDA clearance of IND for second-generation regenerative candidate70% success